This poster was presented at the 29th Annual U.S. Psychiatric & Mental Health Congress, held October 21-24, 2016, in San Antonio, Texas.
Background: This pooled analysis of 2 double-blind, randomized, multicenter, phase 3 studies (NCT01529515 and NCT01515423) evaluated the predictors of improvement or worsening of schizophrenia-related caregiver burden following treatment with paliperidone palmitate 1-month (PP1M) and 3-month (PP3M) formulations.
Methods: Caregivers (family members/friends who had ≥1 hour of contact per week with the patients treated with PP1M) were offered to complete the involvement evaluation questionnaire (IEQ; 31 items; each item score: 0-4; total score: sum of 27 items out of the 31 items [0-108]).
Results: A total of 1497 caregivers (mean [SD] age: 51.5 [13.02] years), of whom 49.3% were parents, were included. More than 50% of caregivers spent >32 hours/week in caregiving. Caregivers had significant improvement in IEQ sum scores from baseline to end-of-study (n=756; mean [SD] baseline score: 28.3 [15.34] points; mean [SD] improvement: 8.9 [14.73] points); most improvements were seen in the worrying (2.6 points) and urging (3.7 points) domains. There was a significant relationship between improvement in IEQ sum scores and relapse status (p<0.001) and patient age (p<0.05). Age of diagnosis, long-acting injectable (LAI) use at baseline, and number/duration of prior psychiatric hospitalizations (<24 months) had no significant effect on improvement. Caregiver burden improvement was significant in patients receiving prior oral antipsychotics after switching to LAI, with less leisure days being impacted and less hours spent in caregiving (p<0.001).
Conclusions: Caregiver burden in family members of patients treated for schizophrenia is considerable. Switching from an oral antipsychotic to an LAI can provide a meaningful and significant improvement in caregiver burden.